Do cognitive supplements actually work?
The term "nootropic" has become one of the most commercially elastic words in the supplement industry. It covers everything from well-characterised phospholipid compounds with decades of clinical trial data to mushroom extracts studied almost exclusively in animal models. Grouping them together, as most supplement brands do, creates the impression of a unified category with a consistent evidence base. That impression is misleading.
This article examines five ingredients that appear most frequently in cognitive supplement formulations: citicoline, phosphatidylserine, lion's mane, bacopa monnieri, and ginkgo biloba. Each has a different evidence story. Some of that evidence is genuinely encouraging, in specific populations, at specific doses, for specific outcomes. Much of it is preliminary, inconsistently replicated, or limited to populations with existing cognitive impairment. The honest answer to the question in the title is: a few show modest, population-specific signals; most do not yet meet the bar for confident recommendation in healthy adults.
What "cognitive function" actually means
Before examining evidence, it is worth pausing on the outcome. "Cognitive function" is not a single thing. It encompasses memory consolidation and retrieval, processing speed, executive function and planning, attention and working memory, language, and long-term resistance to neurodegeneration. An intervention can improve one domain while having no measurable effect on others. A supplement that sharpens attention in sleep-deprived students tells us nothing about its effect on episodic memory in older adults with mild cognitive impairment.
Much of the cognitive supplement literature uses composite outcome scores, computerised battery tests, and self-reported measures that vary substantially between trials. Effect sizes, when positive, tend to be modest and often fall within the range plausibly attributable to practice effects, expectation, or test-retest variability. This is not a reason to dismiss the evidence, but it is a reason to read it carefully.
Citicoline
Citicoline (cytidine diphosphocholine) is a naturally occurring compound involved in phosphatidylcholine synthesis, a major structural component of neuronal membranes. When ingested, it is hydrolysed to cytidine and choline, both of which cross the blood-brain barrier and are thought to support membrane integrity and cholinergic neurotransmission.
The clinical evidence is more substantive than for most ingredients in this category. A 2021 randomised controlled trial by McGlade and colleagues, published in the Journal of Nutrition, found that 500 mg per day of citicoline over 12 weeks improved attention and psychomotor speed in healthy middle-aged adults compared with placebo (McGlade et al., 2021, n=100). An earlier trial by the same group in younger adults reported improvements in motor speed and attention at the same dose (McGlade et al., 2012, n=60). A meta-analysis by Jasielski and colleagues (2020) covering 14 trials and approximately 1,000 participants found modest benefits across multiple small trials for memory and attention, though the authors noted substantial heterogeneity in populations and outcome measures.
The evidence is more robust in clinical populations. In patients with mild vascular cognitive impairment, citicoline has been studied as an adjunct intervention with encouraging results on cognitive composite scores (Alvarez-Sabin and Roman, 2011). In acute stroke settings, trials have been less consistent, and the Cochrane review by Fioravanti and Yanagi (2005) found insufficient evidence to support routine use in dementia.
The population most plausibly likely to benefit from citicoline supplementation is adults over 40 with age-related attentional decline, not young healthy adults seeking performance enhancement. In the latter group, effect sizes are small and the clinical significance is uncertain. The compound appears well tolerated at studied doses, with no major safety concerns identified in trials up to a year in duration.
Phosphatidylserine
Phosphatidylserine is a phospholipid concentrated in neuronal membranes, where it is involved in cell signalling, apoptosis regulation, and the maintenance of membrane fluidity. It is the only cognitive supplement to have received a qualified health claim from the US Food and Drug Administration, though that claim is explicitly qualified: "very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of dementia in the elderly." The qualification is doing important work in that sentence.
The earlier clinical literature used bovine-derived phosphatidylserine, which differs structurally from the soy-derived form now used in most supplements following BSE-related concerns. This complicates direct comparison across trials. A Cochrane review by Richter and colleagues (2010) found that the bovine-derived form showed modest benefits for cognitive decline in older adults, but noted that the evidence base was limited and that findings could not be reliably extrapolated to soy-derived preparations.
More recent trials with soy-derived phosphatidylserine report positive effects on memory and verbal learning in older adults with age-associated memory impairment, though sample sizes tend to be small (Kato-Kataoka et al., 2010, n=78; Richter et al., 2013, n=120). A trial in children with attention difficulties showed some effect on attention and working memory (Hirayama et al., 2014), though this population is distinct enough that findings should not be generalised.
In healthy young adults without baseline cognitive impairment, the evidence for phosphatidylserine is thin. There is no strong rationale for using it as a performance enhancer in this group. The more defensible application remains age-related cognitive decline, where the signal, though modest in magnitude and not yet definitive, is at least biologically plausible and partially supported by controlled trials.
Lion's mane
Lion's mane (Hericium erinaceus) is an edible mushroom whose cognitive claims rest primarily on its content of hericenones and erinacines, compounds that in preclinical studies appear to stimulate nerve growth factor (NGF) synthesis. NGF supports neuronal survival and plasticity, and the hypothesis that oral lion's mane supplementation could meaningfully influence brain NGF levels is biologically plausible. It is also, as yet, not established in human trial evidence.
The human clinical literature is small and methodologically limited. The most frequently cited trial, by Mori and colleagues (2009), found that 1,000 mg three times daily of lion's mane powder improved cognitive scores on the Revised Hasegawa Dementia Scale in older adults with mild cognitive impairment over 16 weeks, with scores declining again after discontinuation (Mori et al., 2009, n=30, Journal of Phytotherapy Research). This is an interesting signal, but the trial is small, the outcome measure is not widely used in contemporary cognitive research, and there is no independent large-scale replication.
A 2020 trial by Saitsu and colleagues in older adults without diagnosed impairment reported improved scores on a Japanese cognitive assessment battery with 1,800 mg per day of lion's mane over 12 weeks (Saitsu et al., 2019, n=31). Again, small sample, modest effect, single study. A 2023 double-blind crossover trial by Docherty and colleagues tested a lower-dose standardised extract in healthy young adults and found acute improvements in processing speed and working memory on computerised tasks (Docherty et al., 2023, n=41, Nutrients). This is a useful addition to the literature, though the crossover design and reliance on computerised cognitive batteries make interpretation cautious.
The honest characterisation of the lion's mane evidence is: promising preclinical biology, a small cluster of positive but underpowered human trials, and no definitive large-scale replication. The ingredient warrants continued investigation, but the marketing language that currently surrounds it has substantially outrun the evidence.
Bacopa monnieri
Bacopa monnieri is an Ayurvedic herb whose active constituents, bacosides, are proposed to modulate synaptic transmission, reduce oxidative stress in neuronal tissue, and support acetylcholinesterase activity. It has one of the more consistent bodies of evidence among cognitive supplements, though with important caveats about effect size and time course.
A 2012 meta-analysis by Pase and colleagues identified nine double-blind placebo-controlled trials and found consistent improvements in free recall memory with bacopa supplementation (Pase et al., 2012, Psychopharmacology). The analysis noted that benefits were most pronounced for delayed recall, were observed in both younger and older adults, and that cognitive effects appeared to require at least 8 to 12 weeks of supplementation rather than being acute. Effect sizes were small to moderate and the authors flagged that most trials were conducted by research groups with connections to commercial suppliers, which introduces the possibility of publication bias and likely inflates the observed effect sizes.
Stough and colleagues published two well-designed Australian trials using a standardised extract (CDRI 08, also known as KeenMind) that reported improvements in verbal learning and memory consolidation at 300 mg per day over 12 weeks in healthy adults aged 18 to 65 (Stough et al., 2001; Stough et al., 2008). A more recent trial by Calabrese and colleagues (2008) found improvements in working memory and mood in healthy older adults, though sample sizes remained modest (n=54).
The case for bacopa is more developed than for lion's mane, but it requires realistic expectations: the effect appears to be on memory consolidation rather than acute cognition, takes weeks to manifest, and is modest in magnitude. It is also worth noting that most positive trials use standardised extract preparations, and the evidence does not transfer straightforwardly to products of unknown bacosides content.
Ginkgo biloba
Ginkgo biloba is one of the most extensively studied herbal interventions in medicine, which makes its current evidence status particularly instructive. Despite decades of research and hundreds of trials, the clinical evidence for ginkgo in cognitive function does not support the confident claims commonly made for it.
The two largest and most rigorous trials are the GuidAge study and the Ginkgo Evaluation of Memory (GEM) study. The GEM trial, published in JAMA by DeKosky and colleagues (2008), was a randomised double-blind placebo-controlled trial of 3,069 community-dwelling older adults followed for a median of 6.1 years, testing whether 240 mg per day of ginkgo extract (EGb 761) could reduce the incidence of dementia. It did not. There was no significant difference in dementia incidence between treatment and placebo groups (DeKosky et al., 2008, JAMA). The GuidAge study, published in Lancet Neurology by Vellas and colleagues (2012), reached the same conclusion in 2,854 participants over five years.
Earlier smaller trials, many of which generated the positive signals that built ginkgo's reputation, were underpowered and likely inflated by small-study effects. A Cochrane review by Birks and Grimley Evans (2009), updated subsequently, concluded that the evidence for ginkgo in preventing cognitive decline or dementia was not convincing and that the overall body of evidence did not support a recommendation.
In younger healthy adults, some trials have reported modest acute effects on attention and processing speed, but these findings are not consistent across studies and do not appear to translate into meaningful real-world performance differences. The current weight of evidence does not support ginkgo as an effective cognitive intervention in either prevention or performance enhancement contexts. This does not mean future evidence will not emerge, but the existing evidence, including two very large well-designed prevention trials, is notably negative for the outcomes most commonly claimed.
What the pattern across five ingredients tells us
Looking across these five ingredients, a few observations emerge that are relevant beyond the individual entries.
First, the population matters more than the ingredient in most cases. Citicoline and phosphatidylserine show their most defensible signals in older adults with age-related decline, not in healthy young adults. Bacopa shows effects across age groups but requires realistic expectations about magnitude and time course. Marketing these ingredients as universal cognitive enhancers misrepresents who they might help. Across all five ingredients, the effects that do appear are more consistent with correction of suboptimal function than with enhancement beyond a normal baseline.
Second, study quality is highly variable, and effect sizes in small positive trials almost always shrink or disappear in larger, better-powered replication. Lion's mane is at the stage where small trials generate promising signals. Ginkgo is at the stage where large trials have tested those signals and found them substantially weaker than expected. This is the normal trajectory of a literature, and premature confidence at the small-trial stage is a predictable error.
Third, mechanism is not outcome. The fact that hericenones stimulate NGF synthesis in cell cultures does not establish that oral lion's mane supplementation meaningfully alters neuronal NGF levels in humans, let alone that this translates to measurable cognitive benefit. Mechanistic plausibility is a reason to investigate, not a reason to conclude.
Fourth, combination products make attribution impossible. Most commercial "nootropic" formulations combine several of these ingredients at doses that differ from those studied in individual trials, alongside other compounds. If a combination product produces a benefit, there is no way to attribute it to any single constituent, and the dose of each ingredient may be below the threshold studied in isolation.
None of this means cognitive supplements are without any value. It means the honest framing is: two ingredients (citicoline, phosphatidylserine) show modest, population-specific signals that are clinically plausible; one (bacopa) shows consistent small effects on memory consolidation in controlled trials; one (lion's mane) is genuinely promising but prematurely celebrated; and one (ginkgo) has been tested at scale and found wanting for its primary marketed claims.
That is a more complicated answer than "take this for your brain." It is also the accurate one.
What can reasonably be concluded
Of the five ingredients reviewed here, citicoline and phosphatidylserine have the most developed clinical evidence, and that evidence is most relevant to adults over 40 with age-related attentional or memory concerns rather than to healthy younger adults seeking performance enhancement. Bacopa has a reasonably consistent body of trial evidence for memory consolidation, though effect sizes are modest and most studies have methodological limitations. Lion's mane is supported by preclinical biology and a small cluster of underpowered trials, none of which constitute adequate evidence for confident clinical recommendation. Ginkgo's evidence, despite being the most extensive of the five, does not support the claims most commonly made for it.
The commercial framing of cognitive supplements as broadly effective nootropics with universal applicability is not supported by the evidence reviewed here. Targeting and expectation management matter considerably, and most of the modest signals that do exist are population-specific, dose-specific, and require weeks of consistent use before any effect might be expected.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.
Key references
Alvarez-Sabin, J. and Roman, G.C. (2011) 'Citicoline in vascular cognitive impairment and vascular dementia after stroke', Stroke, 42(1 Suppl), pp. S40-S43. https://doi.org/10.1161/STROKEAHA.110.606509
Birks, J. and Grimley Evans, J. (2009) 'Ginkgo biloba for cognitive impairment and dementia', Cochrane Database of Systematic Reviews, Issue 1. https://doi.org/10.1002/14651858.CD003120.pub3
Calabrese, C. et al. (2008) 'Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly', Journal of Alternative and Complementary Medicine, 14(6), pp. 707-713. https://doi.org/10.1089/acm.2008.0018
DeKosky, S.T. et al. (2008) 'Ginkgo biloba for prevention of dementia: a randomized controlled trial', JAMA, 300(19), pp. 2253-2262. https://doi.org/10.1001/jama.2008.683
Docherty, S. et al. (2023) 'The acute and chronic effects of lion's mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study', Nutrients, 15(22), 4842. https://doi.org/10.3390/nu15224842
Fioravanti, M. and Yanagi, M. (2005) 'Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly', Cochrane Database of Systematic Reviews, Issue 2. https://doi.org/10.1002/14651858.CD000269.pub3
Hirayama, S. et al. (2014) 'The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder', Journal of Human Nutrition and Dietetics, 27(Suppl 2), pp. 284-291. https://doi.org/10.1111/jhn.12090
Jasielski, P. et al. (2020) 'Application of citicoline in neurological disorders: a systematic review', Nutrients, 12(10), 3113. https://doi.org/10.3390/nu12103113
Kato-Kataoka, A. et al. (2010) 'Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints', Journal of Clinical Biochemistry and Nutrition, 47(3), pp. 246-255. https://doi.org/10.3164/jcbn.10-62
McGlade, E. et al. (2012) 'Improved attentional performance following citicoline administration in healthy adult women', Food and Nutrition Sciences, 3(6), pp. 769-773. https://doi.org/10.4236/fns.2012.36103
McGlade, E. et al. (2021) 'The effect of citicoline supplementation on motor speed and attention in adolescent males', Journal of Attention Disorders, 25(1), pp. 12-22. https://doi.org/10.1177/1087054715593633
Mori, K. et al. (2009) 'Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial', Phytotherapy Research, 23(3), pp. 367-372. https://doi.org/10.1002/ptr.2634
Pase, M.P. et al. (2012) 'The cognitive-enhancing effects of bacopa monnieri: a systematic review of randomized, controlled human clinical trials', Journal of Alternative and Complementary Medicine, 18(7), pp. 647-652. https://doi.org/10.1089/acm.2011.0367
Richter, Y. et al. (2013) 'The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints', Clinical Interventions in Aging, 8, pp. 557-563. https://doi.org/10.2147/CIA.S40348
Saitsu, Y. et al. (2019) 'Improvement of cognitive functions by oral intake of Hericium erinaceus', Biomedical Research, 40(4), pp. 125-131. https://doi.org/10.2220/biomedres.40.125
Stough, C. et al. (2001) 'The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects', Psychopharmacology, 156(4), pp. 481-484. https://doi.org/10.1007/s002130100815
Stough, C. et al. (2008) 'Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning', Phytotherapy Research, 22(12), pp. 1629-1634. https://doi.org/10.1002/ptr.2537
Vellas, B. et al. (2012) 'Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial', Lancet Neurology, 11(10), pp. 851-859. https://doi.org/10.1016/S1474-4422(12)70206-5
For individual ingredient evidence, see the Citicoline, Phosphatidylserine, Lion's Mane, Bacopa, and Ginkgo Biloba entries in the Evidentia library.